ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2519

Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate

Anubha Gupta1, Chiara Zecchin1, Elena Fisheleva1,2, Mark Layton3 and Stefano Zamuner4, 1GlaxoSmithKline, Stevenage, United Kingdom, 2Currently at Biomarin UK Ltd, London, United Kingdom, 3ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 4Clinical Pharmacology, GlaxoSmithKline, Stevenage, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cytokines, pharmacokinetics and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: GSK3196165 is an anti-GM-CSF mAb being developed for RA. In a phase IIb dose-finding study (NCT02504671), RA patients with inadequate response to methotrexate were administered placebo or GSK3196165 (22.5, 45, 90, 135 and 180 mg SC 5 weekly doses followed by administration every other week for 50 weeks) with background methotrexate therapy. The study results are reported in a separate abstract.This analysis aimed to characterize exposure-efficacy relationship for DAS28(CRP), ACR20 and ACR50, and describe the time course of change in DAS28(CRP).

Methods: All available PK data from 222 randomized patients and PK data from previous studies were used to develop a population PK model. ACR data at Week 12 and time-course DAS28(CRP) were used for exposure-response analyses and analysed using both graphically and model-based approaches.

Change from baseline in DAS28(CRP) and proportion of ACR20/50 responders were plotted for placebo group and quartiles of GSK3196165 steady-state trough concentrations. Longitudinal data for DAS28(CRP) was modelled using an indirect response model to describe the treatment effect, placebo effect was described by an exponential decline. Exposure-efficacy relationship for ACR20 and ACR50 at Week 12 was analysed using logistic regression analysis. PK/PD models for DAS28(CRP) and ACR20/50 were utilized to inform optimal dose and regimen for subsequent clinical trials.

Results: GSK3196165 exhibited linear PK over the tested dose range with a mean systemic clearance (CL) of 0.93 L/day and bioavailability (F) of 0.35 in healthy volunteers which is significantly higher CL and lower F than a typical monoclonal antibody. The apparent clearance in RA patients (CL/F) was 2.5 times faster than predicted, resulting in significantly lower trough levels at steady-state. The elimination half-life in RA population was estimated to be 10 days.

At Week 12, higher response for both DAS28(CRP) and ACR20/50 was associated with higher exposures of GSK3196165. The highest quartile showed a median change from baseline of 1.63 points over placebo for DAS28(CRP), while ACR20 and ACR50 showed 59% and 34% response, respectively (12% and 9% in the placebo group). Using population PK and PK/PD models, a dose of 150 mg weekly is predicted to achieve a steady state trough concentration of 2,500 ng/mL, DAS28(CRP) change from baseline of 1.67 over placebo, and ACR50 response rate of 44%.

Conclusion: GSK3196165 has high CL/F compared to typical monoclonal antibody against soluble cytokines. A clear exposure-response relationship was observed with a greater efficacy achieved at higher trough concentration. The predictions suggest that weekly SC administration of 150 mg GSK3196165 can be associated with the clinically-meaningfully higher response rate in both DAS28(CRP) and ACR50 compared with the observed data in study NCT02504671. Further studies are now required to confirm the expected clinical benefit of increased exposure with weekly dosing of GSK3196165 in patients with RA.


Disclosure: A. Gupta, GlaxoSmithKline, 1, 3; C. Zecchin, GlaxoSmithKline, 1, 3; E. Fisheleva, GlaxoSmithKline, 1; M. Layton, GlaxoSmithKline, 1, 3; S. Zamuner, GlaxoSmithKline, 1, 3.

To cite this abstract in AMA style:

Gupta A, Zecchin C, Fisheleva E, Layton M, Zamuner S. Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/exposure-efficacy-analysis-in-dmard-inadequate-response-rheumatoid-arthritis-patients-treated-with-gsk3196165-along-with-methotrexate/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exposure-efficacy-analysis-in-dmard-inadequate-response-rheumatoid-arthritis-patients-treated-with-gsk3196165-along-with-methotrexate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology